Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RANI Stock Chart & Stats
$0.74
-$0.04(-3.15%)
At close: 4:00 PM EST
$0.74
-$0.04(-3.15%)
Day’s Range― - ―
52-Week Range$0.39 - $3.87
Previous CloseN/A
Volume228.85K
Average Volume (3M)1.27M
Market Cap
$91.53M
Enterprise Value$36.49M
Total Cash (Recent Filing)$49.71M
Total Debt (Recent Filing)$4.32M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding99,721,924
10 Day Avg. Volume1,400,656
30 Day Avg. Volume1,273,637
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue22.35
Enterprise Value/Gross Profit29.81
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$7.00Price Target Upside845.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$9.00M
Bulls Say, Bears Say
Bulls Say
Cash Runway And Pipeline OptionalityThe license agreement and concurrent financing extend cash resources and support development of the internal pipeline for multiple programs, preserving strategic optionality and lowering near-term financing pressure.
Clinical AdvancementInitiation of a Phase 1 study for RT-114 and the multiple-dose portion of the trial may provide the first human pharmacodynamic signals for the RaniPill, reducing clinical development risk and supporting value creation.
Partnership ValidationCollaboration with Chugai provides external validation of the RaniPill technology and signals confidence in manufacturability and regulatory approach, which may attract additional pharmaceutical licensing partners.
Bears Say
Competitive Efficacy CeilingRT-114 is unlikely to match the highest weight-loss levels achieved by the most potent drugs in the class, which may limit its use among patients seeking maximal reductions.
Development And Partnering UncertaintyClinical development risk, regulatory risk, and partnering outcomes represent key uncertainties that could undermine the investment thesis if trials or negotiations fail to meet expectations.
Manufacturing And Regulatory Scale-up RiskManufacturing scale-up and regulatory approval remain significant risks for oral delivery of biologics, and difficulties scaling RaniPill production could impede commercialization plans.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings’s price range in the past 12 months?
Rani Therapeutics Holdings lowest stock price was $0.39 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings’s market cap?
Rani Therapeutics Holdings’s market cap is $91.53M.
When is Rani Therapeutics Holdings’s upcoming earnings report date?
Rani Therapeutics Holdings’s upcoming earnings report date is May 13, 2026 which is in 29 days.
How were Rani Therapeutics Holdings’s earnings last quarter?
Rani Therapeutics Holdings released its earnings results on Mar 26, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.048 by -$0.022.
Is Rani Therapeutics Holdings overvalued?
According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued.
Does Rani Therapeutics Holdings pay dividends?
Rani Therapeutics Holdings does not currently pay dividends.
What is Rani Therapeutics Holdings’s EPS estimate?
Rani Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rani Therapeutics Holdings have?
Rani Therapeutics Holdings has 99,721,924 shares outstanding.
What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?
Rani Therapeutics Holdings reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.048. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (845.95% Upside)
$7.00 (845.95% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
-718.54%
Trailing 12-Months
Asset Growth
60.02%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$7.00
▲(845.95% Upside)
Technical Analysis
Ownership Overview
29.28% Insiders
5.22% Mutual Funds
37.25% Other Institutional Investors
23.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---